Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

By afschroeder • November 10, 2025

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. Eur Urol Oncol. 2025 Nov 8:S2588-9311(25)00287-1. doi: 10.1016/j.euo.2025.10.013. Epub ahead of print. PMID: 41207813.

Tags: age, Androgen antagonists, Antineoplastic agents, dasatinib, DOM STAT, Epithelial-mesenchymal transition, Gene expression regulation, General Internal Medicine, Hematology/Oncology, MAP kinase signaling, neoadjuvant therapy, Prostatectomy, Prostatic neoplasm, Publications, Veterans Administration

Unmet social needs and colorectal cancer testing at 45-49 since the 2021 USPSTF recommendation

Chen KL, Mangione CM, Shih YT. Unmet social needs and colorectal cancer testing at 45-49 since the 2021 USPSTF recommendation. J Natl Cancer Inst. 2025[...]

Adaptive Sports Medicine: Health, Rehabilitation, and Training for Para-Athletes

Eapen BC. Adaptive Sports Medicine: Health, Rehabilitation, and Training for Para-Athletes. Phys Med Rehabil Clin N Am. 2026 Feb;37(1):xi-xii. doi: 10.1016/j.pmr.2025.10.002. Epub 2025 Oct 22.[...]

Heavy Chains, Heavy Consequences: A Case of Concomitant Heavy Chain Amyloidosis and Heavy Chain Deposition Disease

Amoh BK, Ghanem G, Zuckerman JE, Bruss Z, Chuang K. Heavy Chains, Heavy Consequences: A Case of Concomitant Heavy Chain Amyloidosis and Heavy Chain Deposition[...]